Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) today announced that retrospective analyses of integrated efficacy data and immuno-safety ... read more

Santarus, Inc. (NASDAQ: SNTS) today announced that new data from a clinical study to assess the efficacy and safety of eight weeks of open-label ... read more

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will make presentations at ... read more

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended September 30, 2011. Key financial ... read more

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that a retrospective analysis ... read more

Santarus, Inc. (NASDAQ:SNTS) today announced the presentation of an analysis of pooled data from its two Phase III clinical studies indicating that ... read more

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release third quarter 2011 financial results after market close on Monday, November 7, 2011. Santarus ... read more

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated ... read more

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will make presentations at the following investment conferences: ... read more